Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Description: Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Psoriasis Therapeutics market. The report identifies the key trends shaping and driving the global Psoriasis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Psoriasis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Psoriasis Therapeutics market. Its scope includes:
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Psoriasis Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Psoriasis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Psoriasis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Psoriasis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Psoriasis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Psoriasis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Psoriasis Therapeutics market landscape? – Identify, understand and capitalize.

Contents:
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Psoriasis Therapeutics Market - Introduction
2.1 Overview
2.2 Etiology and Pathophysiology
2.3 Sign and Symptoms
2.4 Epidemiology
2.5 Diagnosis
2.6 Treatment and Management Pattern
2.6.1 Topical Therapy
2.6.2 Phototherapy
2.6.3 Systemic Therapy
2.7 GlobalData Pipeline Report Guidance
3 Psoriasis Therapeutics - Market Characterization
3.1 Major Markets, Market Size (2005-2010)
3.2 Major Markets, Market Forecast (2010-2018)
3.3 Psoriasis Therapeutics Market Size (2005-2010) – The US
3.4 Psoriasis Therapeutics Market Forecast (2010-2018) – The US
3.5 Psoriasis Therapeutics Market Size (2005-2010) – France
3.6 Psoriasis Therapeutics Market Forecast (2010-2018) – France
3.7 Psoriasis Therapeutics Market Size (2005-2010) – Germany
3.8 Psoriasis Therapeutics Market Forecast (2010-2018) – Germany
3.9 Psoriasis Therapeutics Market Size (2005-2010) – Italy
3.10 Psoriasis Therapeutics Market Forecast (2010-2018) – Italy
3.11 Psoriasis Therapeutics Market Size (2005-2010) – Spain
3.12 Psoriasis Therapeutics Market Forecast (2010-2018) – Spain
3.14 Psoriasis Therapeutics Market Forecast (2010-2018) – The UK
3.15 Psoriasis Therapeutics Market Size (2005-2010) – Japan
3.16 Psoriasis Therapeutics Market Forecast (2010-2018) – Japan
3.17 Drivers and Barriers for the Psoriasis Therapeutics Market
3.17.1 Drivers for the Psoriasis Therapeutics Market
3.17.2 Barriers for the Psoriasis Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Psoriasis Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Product Profile for the Major Marketed Products in the Psoriasis Therapeutics Market – Topical Therapy
4.2.1 Corticosteroids
4.2.2 Vitamin D Derivatives
4.2.3 Taclonex (Calcipotriene in Combination with Betamethasone Dipropionate)
4.2.4 Tazorac (tazarotene)
4.3 Product Profile for the Major Marketed Products in the Psoriasis Therapeutics Market – Systemic Therapy
4.3.1 Methotrexate
4.3.2 Cyclosporin
4.3.3 Acitretin
4.3.4 Enbrel (etanercept)
4.3.5 Humira (adalimumab)
4.3.6 Amevive (alefacept)
4.3.7 Remicade (infliximab)
4.3.8 Stelara (ustekinumab)
5 Psoriasis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Psoriasis Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 Psoriasis Therapeutics – Phase III Pipeline
5.3.2 Psoriasis Therapeutics – Phase II/III Pipeline
5.3.3 Psoriasis Therapeutics – Phase II Pipeline
5.3.4 Psoriasis Therapeutics – Phase I/II Pipeline
5.3.5 Psoriasis Therapeutics – Phase I Pipeline
5.3.6 Psoriasis Therapeutics – Preclinical Pipeline
5.3.7 Psoriasis Therapeutics – Discovery Pipeline
5.4 Psoriasis Therapeutics – Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Psoriasis Therapeutics – Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs Under Clinical Development
5.7.1 Anti-CD6 (T1h)
5.7.2 Apremilast (CC10004)
5.7.3 Briakinumab (ABT-874)
5.7.4 Secukinumab (AIN457)
5.7.5 Tofacitinib (tasocitinib, CP-690,550)
5.7.6 Voclosporin (LX211, LUVENIQ, ISA-247)
5.8 Key Takeaway

6 Psoriasis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Psoriasis Therapeutics Clinical Trials

7 Psoriasis Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Psoriasis Therapeutics: Implications for Future Market Competition
8 Psoriasis Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Pfizer, Inc.
8.2.2 Celgene Corporation
8.2.3 Isotechnika Pharma, Inc
8.2.4 Can-Fite Biopharma Ltd.
8.2.5 Abbott Laboratories
8.2.6 Novartis AG
8.2.7 Biocon Limited
8.2.8 Other Companies in the Psoriasis Therapeutics Market
9 Psoriasis Therapeutics - Licensing and Partnership Deals
10 Psoriasis Therapeutics - Licensing and Partnership Deals
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Prevalence of Psoriasis
Table 2: Psoriasis Therapeutics Market, Major Markets, Revenue ($bn), 2005–2010
Table 3: Psoriasis Therapeutics Market, Major Markets, Forecast ($bn), 2010–2018
Table 4: Psoriasis Therapeutics Market, The US, Revenue ($bn), 2005–2010
Table 5: Psoriasis Therapeutics Market, The US, Forecast ($bn), 2010–2018
Table 6: Psoriasis Therapeutics Market, France, Revenue ($m), 2005–2010
Table 7: Psoriasis Therapeutics Market, France, Forecast ($m), 2010–2018
Table 8: Psoriasis Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 9: Psoriasis Therapeutics Market, Germany, Forecast ($m), 2010–2018
Table 10: Psoriasis Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 11: Psoriasis Therapeutics Market, Italy, Forecast ($m), 2010–2018
Table 12: Psoriasis Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 13: Psoriasis Therapeutics Market, Spain, Forecast ($m), 2010–2018
Table 14: Psoriasis Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 15: Psoriasis Therapeutics Market, The UK, Forecast ($m), 2010–2018
Table 16: Psoriasis Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 17: Psoriasis Therapeutics Market, Japan, Forecast ($m), 2010–2018
Table 18: Psoriasis Therapeutics – Phase III Pipeline, 2011
Table 19: Psoriasis Therapeutics – Phase II/III Pipeline, 2011
Table 20: Psoriasis Therapeutics – Phase II Pipeline, 2011
Table 21: Psoriasis Therapeutics – Phase I/II Pipeline, 2011
Table 22: Psoriasis Therapeutics – Phase I Pipeline, 2011
Table 23: Psoriasis Therapeutics – Preclinical Pipeline, 2011
Table 24: Psoriasis Therapeutics – Discovery Pipeline, 2011
Table 25: Other Mechanisms of Action From the Figure Above
Table 26: Psoriasis Therapeutics – Most Promising Drugs Under Clinical Development, 2011
Table 27: Psoriasis Therapeutics – Clinical Trials by Country, 2011
Table 28: Psoriasis Therapeutics - Clinical Trials by Phase, 2011
Table 29: Psoriasis Therapeutics - Clinical Trials by Status, 2011
Table 30: Psoriasis Therapeutics - Prominent Sponsors, 2011
Table 31: Psoriasis Therapeutics - Top Companies Participating in Clinical Trials, 2011
Table 32: Pfizer, Inc. – Inflammation and Immunology Pipeline, 2011
Table 33: Pfizer, Inc. – Molecules in Pipeline for Psoriasis, 2011
Table 34: Pfizer, Inc. – Deals, Alliances and Partnerships
Table 35: Celgene Corporation– Inflammation and Immunology Pipeline, 2011
Table 36: Celgene Corporation– Molecules in Pipeline for Psoriasis, 2011
Table 37: Celgene Corporation– Deals, Alliances and Partnerships
Table 38: Iso technika Pharma, Inc.– Inflammation and Immunology Pipeline, 2011
Table 39: Iso technika Pharma, Inc.– Molecules in Pipeline for Psoriasis, 2011
Table 40: Iso technika Pharma, Inc.– Deals, Alliances and Partnerships
Table 41: Can-Fite Biopharma Ltd.– Inflammation and Immunology Pipeline, 2011
Table 42: Can-Fite Biopharma Ltd.– Molecules in Pipeline for Psoriasis, 2011
Table 43: Can-Fite Biopharma Ltd.– Deals, Alliances and Partnerships
Table 44: Abbott Laboratories– Inflammation and Immunology Pipeline, 2011
Table 45: Abbott Laboratories– Molecules in Pipeline for Psoriasis, 2011
Table 46: Abbott Laboratories– Deals, Alliances and Partnerships
Table 47: Novartis AG– Inflammation and Immunology Pipeline, 2011
Table 48: Novartis AG – Molecules in Pipeline for Psoriasis, 2011
Table 49: Novartis AG– Deals, Alliances and Partnerships
Table 50: Biocon Limited– Inflammation and Immunology Pipeline, 2011
Table 51: Biocon Limited – Molecules in Pipeline for Psoriasis, 2011
Table 52: Biocon Limited– Deals, Alliances and Partnerships
Table 53: Psoriasis Therapeutics Market – Future Players
Table 54: Psoriasis Therapeutics: Licensing and Partnership deals

1.2 List of Figures
Figure 1: Overview of Treatment for Psoriasis
Figure 2: Psoriasis Therapeutics Market, Major Markets, Revenue ($bn), 2005–2010
Figure 3: Psoriasis Therapeutics, Market Share ($m, %), 2010
Figure 4: Psoriasis Therapeutics Market, Major Markets, Forecast ($bn), 2010–2018
Figure 5: Psoriasis Therapeutics, Forecast Market Share ($m, %), 2018
Figure 6: Psoriasis Therapeutics Market, The US, Revenue ($bn), 2005–2010
Figure 7: Psoriasis Therapeutics Market, The US, Forecast ($bn), 2010–2018
Figure 8: Psoriasis Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 9: Psoriasis Therapeutics Market, France, Forecast ($m), 2010–2018
Figure 10: Psoriasis Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 11: Psoriasis Therapeutics Market, Germany, Forecast ($m), 2010–2018
Figure 12: Psoriasis Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 13: Psoriasis Therapeutics Market, Italy, Forecast ($m), 2010–2018
Figure 14: Psoriasis Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 15: Psoriasis Therapeutics Market, Spain, Forecast ($m), 2010–2018
Figure 16: Psoriasis Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 17: Psoriasis Therapeutics Market, The UK, Forecast ($m), 2010–2018
Figure 18: Psoriasis Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 19: Psoriasis Therapeutics Market, Japan, Forecast ($m), 2010–2018
Figure 20: Opportunity and Unmet Need in the Psoriasis Therapeutics Market - Topical Therapy, 2011
Figure 21: Opportunity and Unmet Need in the Psoriasis Therapeutics Market - Conventional Systemic Therapy, 2011
Figure 22: Opportunity and Unmet Need in the Psoriasis Therapeutics Market - Biologic Therapy, 2011
Figure 23: Strategic Competitor Assessment of the Major Marketed Products for Psoriasis - Topical Therapy, 2011
Figure 24: Strategic Competitor Assessment of the Major Marketed Products for Psoriasis - Conventional Systemic Therapy, 2011
Figure 25: Strategic Competitor Assessment of the Major Marketed Products for Psoriasis - Biologics, 2011
Figure 26: Psoriasis Therapeutics – Pipeline by Phases of Development, 2011
Figure 27: Psoriasis Therapeutics – Pipeline by Mechanism of Action, 2011
Figure 28: Psoriasis Therapeutics – Technology Trends Analytics Framework, 2011
Figure 29: Psoriasis Therapeutics – Technology Trends Analytics Framework – Description, 2011
Figure 30: Psoriasis Therapeutics – Clinical Trials by Country, 2011
Figure 31: Psoriasis Therapeutics - Clinical Trials by Phase, 2011
Figure 32: Psoriasis Therapeutics - Clinical Trials by Status, 2011
Figure 33: Psoriasis Therapeutics - Overall Sponsors, 2011
Figure 34: Psoriasis Therapeutics - Prominent Sponsors, 2011
Figure 35: Psoriasis Therapeutic Clinical Trials - Company Sponsors by Phase, 2011
Figure 36: Psoriasis Therapeutics Market, Drivers and Restraints 2011
Figure 37: Implications for Future Market Competition in the Psoriasis Therapeutics Market, 2011
Figure 38: Psoriasis Therapeutics – Pipeline by Company, 2011
Figure 39: GlobalData Market Forecasting Model

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 |
| Web Address: [http://www.researchandmarkets.com/reports/1934400/](http://www.researchandmarkets.com/reports/1934400/) |
| Office Code: SCD21W3U |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World